Insulin degludec allows for better glycaemic control with a lower risk of hypoglycaemia in patients with chronic kidney disease and type 2 diabetes

María Dolores García de Lucas; Beatriz Avilés Bueno; Francisco Rivas Ruiz; Julián Olalla Sierra

doi:10.1016/j.diabres.2020.108094

Insulin degludec allows for better glycaemic control with a lower risk of hypoglycaemia in patients with chronic kidney disease and type 2 diabetes

Diabetes Res Clin Pract. 2020 Apr:162:108094. doi: 10.1016/j.diabres.2020.108094. Epub 2020 Feb 27.

Authors

María Dolores García de Lucas¹, Beatriz Avilés Bueno², Francisco Rivas Ruiz³, Julián Olalla Sierra⁴

Affiliations

¹ Internal Medicine Department, Hospital Costa del Sol, Marbella, Málaga, Spain. Electronic address: gdelucaslola@gmail.com.
² Nephrology Department, Hospital Costa del Sol, Marbella, Málaga, Spain.
³ Research Support Unit, Hospital Costa del Sol, Marbella, Málaga, Spain.
⁴ Internal Medicine Department, Hospital Costa del Sol, Marbella, Málaga, Spain.

PMID: 32113852
DOI: 10.1016/j.diabres.2020.108094

Abstract

We conducted a retrospective observational study to demonstrate that switching to insulin degludec from other long-acting insulins reduces the risk of hypoglycaemia events and improves glycaemic control in patients with type 2 diabetes and stage 2-3B chronic kidney disease.

Publication types

Observational Study

MeSH terms

Aged
Blood Glucose / analysis*
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Female
Humans
Hypoglycemia / chemically induced
Hypoglycemia / prevention & control*
Hypoglycemic Agents / therapeutic use
Insulin, Long-Acting / therapeutic use*
Male
Middle Aged
Prognosis
Renal Insufficiency, Chronic / complications
Renal Insufficiency, Chronic / drug therapy*
Retrospective Studies
Risk Factors

Substances

Blood Glucose
Hypoglycemic Agents
Insulin, Long-Acting
insulin degludec